National Resource Center for Academic Detailing [NaRCAD]
NARCAD
  • About
    • Why We Matter
    • Testimonials
    • Our Team
    • Contact Us
  • Tools & Resources
    • AD Core Toolkits >
      • Inclusivity Toolkit
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
      • E-Detailing Toolkit
      • Materials Toolkit
    • AD Literature Archives
  • Webinars
    • Webinar Series
    • E-Detailing Webinars
    • E-Detailing Roundtables
  • Blog & E-News
    • Best Practices Blog
    • E-Newsletter
  • Community
    • Discussion Forum
    • Peer Connection Program
    • Detailing Partners
  • EVENTS
    • Training Series
    • CONFERENCE SERIES
    • AD Summit Series
    • Present at NaRCAD2023
    • THE CONFERENCE HUB
  • About
    • Why We Matter
    • Testimonials
    • Our Team
    • Contact Us
  • Tools & Resources
    • AD Core Toolkits >
      • Inclusivity Toolkit
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
      • E-Detailing Toolkit
      • Materials Toolkit
    • AD Literature Archives
  • Webinars
    • Webinar Series
    • E-Detailing Webinars
    • E-Detailing Roundtables
  • Blog & E-News
    • Best Practices Blog
    • E-Newsletter
  • Community
    • Discussion Forum
    • Peer Connection Program
    • Detailing Partners
  • EVENTS
    • Training Series
    • CONFERENCE SERIES
    • AD Summit Series
    • Present at NaRCAD2023
    • THE CONFERENCE HUB

The DETAILS BLOG

Capturing Stories from the Field: Reflections, Challenges, & Best Practices

Curbing Informational Pollution

1/15/2016

1 Comment

 
Jerry Avorn, MD, Co-Director of NaRCAD, Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital

Tags: Evidence-Based Medication, Jerry Avorn, Medications
Picture
​Consider the following recent news development:
            A large multinational company is discovered to have purposely hidden the risks of one of its best-selling products by suppressing information about its adverse effects and presenting only a selective set of data about its impact, to cast it in a more favorable light than was accurate. The magnitude of this distortion was so great that it posed health risks for hundreds of thousands of people throughout the industrialized world.  The company admitted guilt and said it would try to do better in the future. No criminal charges were pressed, and none may ever be.
 
            I refer, of course, to Volkswagen. Last year, the carmaker was found to have rigged the pollution-control devices in its diesel cars to make it appear they were reducing emissions, but only when the car was being inspected. The rest of the time the autos spewed out pollutants far in excess of the allowed limits.  The engineers and executives who perpetrated this enormous hoax were not demons. They were employees of a large corporation who let the need for profit (or shareholder value, a more polite term) push them beyond the limits of accurately presenting data about their products. These things happen in large companies, including drugmakers, who have in the last decade or so had to pay over $15 billion in legal settlements, most of which dealt with such mis-statements of benefits and harms. Nothing personal; it’s just business.
 
            Anyone who is shocked about this should go back to review the imperatives of corporate life, as defined by the Nobel Prize-winning economist Milton Friedman. In a 1970 article, he noted that “There is one and only one social responsibility of business -- to use its resources and engage in activities designed to increase its profits….” Unfortunately, the second half of that sentence is often omitted: “…so long as it stays within the rules of the game, which is to say, engages in open and free competition without deception or fraud.” In an era of an overstretched and sometimes overmatched FDA, there’s a greater need than ever to present clinicians with an accurate depiction of the good and harm that medications can do.
 
            Of course, academic detailing is about far more than just correcting the excesses or misstatements of drugmakers. Our job is to present a comprehensive, un-skewed overview of the benefits and risks of medications and other health care decisions. But in doing so, we sometimes have to address misconceptions generated by some drugmakers who are, I suppose, just trying to give their shareholders a good return on their investment.  Whether a company makes cars or drugs, its staff at all levels are under tremendous pressure to increase sales.  This can often draw otherwise reasonable employees close to – or sometimes over – the line of what’s deceptive.
 
            In academic detailing, we don’t have to worry about sales goals or profit margins.  The only currency we need to maximize is accurate evidence; our only “shareholders” are patients and the clinicians who care for them. In a way, that’s the easiest and best part of our jobs.

1 Comment
Light info link
3/30/2016 10:23:50 am

Great post, Thank for share with us

Reply



Leave a Reply.

    Highlighting Best Practices

    We highlight what's working in clinical education through interviews, features, event recaps, and guest blogs, offering clinical educators the chance to share successes and lessons learned from around the country & beyond.

    Search Archives
    by Topic:

    All
    Autism
    Cancer
    Cardiovascular Health
    Chronic Illness
    CME
    Conference
    COVID 19
    Data
    Deprescribing
    Detailing Visits
    Diabetes
    Director's Letter
    E Detailing
    Elderly Care
    Evaluation
    Evidence Based Medicine
    Expert Trainer Insight Series
    Harm Reduction
    Health Disparities
    Health Policy
    Hepatitis C
    HIV/AIDS
    International
    Jerry Avorn
    LOOPR
    Materials Development
    Medications
    Mental Health
    Obesity
    Opioid Safety
    Pediatrics
    Practice Facilitation
    PrEP
    Primary Care
    Program Management
    Rural AD Programs
    Sexual Health
    Smoking Cessation
    Stigma
    Substance Use
    Sustainability
    Training
    Vaccinations

    RSS Feed


​NaRCAD is a program of the Boston Medical Center, founded at the Division of Pharmacoepidemiology & Pharmacoeconomics [DoPE], at Brigham & Women's Hospital.

​Privacy Notice
Proudly powered by Weebly